Company: Biogen Idec Inc

(Reuters) - More than 40 percent of patients with moderate to severe ulcerative colitis achieved clinical remission from the debilitating condition after a year of taking an experimental drug developed by Japan's Takeda Pharmaceutical Co, according to data from a pivotal late-stage trial.

Moody's Investors Service said Monday that it expects more companies in the health-care industry to start paying dividends, keeping pace with a trend in the broader market.

‘Stick with what’s working.’ Money pros have been saying it for quite a while.  In other words, when you put money to work pick stocks that are leaders not laggards – buy high and sell higher; that’s the trade that has paid.  However, with some leaders advancing 50% or more over a period of only 1 year, investors are starting to wonder how much upside can possibly be left.  Given the outperformance, should you remain bullish on these S&P over achievers? Or is the trading thesis getting a little long in the tooth?